Cargando…
Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology
While several resources exist that interpret therapeutic significance of genomic alterations in cancer, many regional real-world issues limit access to drugs. There is a need for a pragmatic, evidence-based, context-adapted tool to guide clinical management based on molecular biomarkers. To this end...
Autores principales: | Lin, Frank P., Thavaneswaran, Subotheni, Grady, John P., Ballinger, Mandy, Kansara, Maya, Oakes, Samantha R., Desai, Jayesh, Lee, Chee Khoon, Simes, John, Thomas, David M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222322/ https://www.ncbi.nlm.nih.gov/pubmed/34162978 http://dx.doi.org/10.1038/s41698-021-00194-z |
Ejemplares similares
-
A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations
por: Thavaneswaran, Subotheni, et al.
Publicado: (2023) -
The experiences and needs of Australian medical oncologists in integrating comprehensive genomic profiling into clinical care: a nation-wide survey
por: Thavaneswaran, Subotheni, et al.
Publicado: (2021) -
Early circulating tumor DNA dynamics as a pan‐tumor biomarker for long‐term clinical outcome in patients treated with durvalumab and tremelimumab
por: Kansara, Maya, et al.
Publicado: (2022) -
Clinical Response to Seribantumab, an Anti–Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an NRG1 Fusion
por: Thavaneswaran, Subotheni, et al.
Publicado: (2022) -
Curated compendium of human transcriptional biomarker data
por: Golightly, Nathan P., et al.
Publicado: (2018)